18F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma

European Journal of Cancer

Volumn 49, Issue 2, 2013, Pages 395-402

  Carlino, Matteo S ^a,b,c   Saunders, Catherine A B ^c,d   Haydu, Lauren E ^b,d   Menzies, Alexander M ^b,c   Martin Curtis Jr , C ^e   Lebowitz, Peter F ^f   Kefford, Richard F ^a,b,c,d   Long, Georgina V ^a,b,c,d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b MELANOMA INSTITUTE AUSTRALIA   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e GLAXOSMITHKLINE   (United States)

^f Janssen RandD   (United States)

Author keywords

BRAF inhibitor; BRAF mutant; Dabrafenib; FDG PET; Heterogeneity; Metastatic melanoma

Indexed keywords

B RAF KINASE; DABRAFENIB; FLUORODEOXYGLUCOSE F 18; LACTATE DEHYDROGENASE; MUTANT PROTEIN;

ADULT; ARTICLE; CANCER PROGNOSIS; CLINICAL ARTICLE; DRUG UPTAKE; FEMALE; GENETIC HETEROGENEITY; GENOTYPING TECHNIQUE; HUMAN; LUNG METASTASIS; MALE; METASTATIC MELANOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT RESPONSE; VISCERAL METASTASIS; WHOLE BODY PET;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMIDAZOLES; MALE; MELANOMA; MUTATION; OXIMES; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; RADIOPHARMACEUTICALS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84872116067     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.08.018     Document Type: Article

References (36)

1. M. Takata, R. Morita, and K. Takehara Clonal heterogeneity in sporadic melanomas as revealed by loss-of-heterozygosity analysis Int J Cancer 85 4 2000 492 497
2. M. Yancovitz, A. Litterman, and J. Yoon Intra- and inter-tumor heterogeneity of BRAF V600E mutations in primary and metastatic melanoma PLoS ONE 7 1 2012 e29336
3. T.M. Katona, T.D. Jones, and M. Wang Genetically heterogeneous and clonally unrelated metastases may arise in patients with cutaneous melanoma Am J Surg Pathol 31 7 2007 1029 1037
4. J. Lin, Y. Goto, and H. Murata Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression Br J Cancer 104 3 2011 464 468
5. A. Marusyk, V. Almendro, and K. Polyak Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer 12 5 2012 323 334
6. H. Davies, G.R. Bignell, and C. Cox Mutations of the BRAF gene in human cancer Nature 417 6892 2002 949 954
7. Catalogue of somatic mutations in cancer (COSMIC) website. < http://www.sanger.ac.uk/genetics/CGP/cosmic/ >; Wellcome Trust Sanger Institute.
8. K.T. Flaherty, I. Puzanov, and K.B. Kim Inhibition of mutated, activated BRAF in metastatic melanoma N Engl J Med 363 9 2010 809 819
9. P.B. Chapman, A. Hauschild, and C. Robert Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 26 2011 2507 2516
10. G.S. Falchook, G.V. Long, and R. Kurzrock Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial Lancet 379 9829 2012 1893 1901
11. A. Hauschild, J.-J. Grob, and L.V. Demidov Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial Lancet 380 9839 2012 358 365
12. G.J. Kelloff, J.M. Hoffman, and B. Johnson Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development Clin Cancer Res 11 8 2005 2785 2808
13. V. Safar, J. Dupuis, and E. Itti Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab J Clin Oncol 30 2 2011 184 190
14. K. Spaepen Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma Ann Oncol 13 9 2002 1356 1363
15. N.G. Mikhaeel FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma Ann Oncol 16 9 2005 1514 1523
16. W.B. Eubank, and D.A. Mankoff Evolving role of positron emission tomography in breast cancer imaging Semin Nucl Med 35 2 2005 84 99
17. J. Vansteenkiste, B.M. Fischer, C. Dooms, and J. Mortensen Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review Lancet Oncol 5 9 2004 531 540
18. C.H. Holdsworth, R.D. Badawi, and J.B. Manola CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor AJR Am J Roentgenol 189 6 2007 W324 W330
19. S. Basu, T.C. Kwee, and R. Gatenby Evolving role of molecular imaging with PET in detecting and characterizing heterogeneity of cancer tissue at the primary and metastatic sites, a plausible explanation for failed attempts to cure malignant disorders Eur J Nucl Med Mol Imaging 38 6 2011 987 991
20. S. Barollo, G. Pennelli, and F. Vianello BRAF in primary and recurrent papillary thyroid cancers: the relationship with 131I and 2-[18F]fluoro-2-deoxy- D-glucose uptake ability Eur J Endocrinol 163 4 2010 659 663
21. G.A. McArthur, I. Puzanov, and R. Amaravadi Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma J Clin Oncol 30 14 2012 1628 1634
22. Baudy AR, Dogan T, Flores JE, et al. Vemurafenib FDG-PET preclinical imaging outcomes across BRAF V600E mutant and resistant tumors. In: Proceedings of the 103rd annual meeting of the american association for cancer research, 2012 Mar 31-Apr 4, Chicago, Illinois. Philadelphia (PA): AACR; 2012 [abstract nr. 911].
23. M. Gerlinger, A.J. Rowan, and S. Horswell Intratumor heterogeneity and branched evolution revealed by multiregion sequencing N Engl J Med 366 10 2012 883 892
24. H. Young, R. Baum, and U. Cremerius Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group Eur J Cancer 35 13 1999 1773 1782
25. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 3 2000 205 216
26. D. Kahraman, M. Scheffler, and T. Zander Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3′-deoxy-3′-18F-fluorothymidine PET J Nucl Med 52 12 2011 1871 1877
27. R.L. Wahl, H. Jacene, Y. Kasamon, and M.A. Lodge From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors J Nucl Med 50 Suppl. 1 2009 122S 150S
28. F.S. Hodi, S.J. O'Day, and D.F. McDermott Improved survival with ipilimumab in patients with metastatic melanoma.[Erratum appears in N Engl J Med. 2010 Sep 23;363(13):1290] N Engl J Med 363 8 2010 711 723
29. C. Robert, L. Thomas, and I. Bondarenko Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N Engl J Med 364 26 2011 2517 2526
30. J.S. Weber, K.T. Flaherty, and J.R. Infante Updated safety and efficacy results from a phase I/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAFi-naive metastatic melanoma ASCO Meeting Abstr 30 15-suppl. 2012 8510
31. K.Y. Su, H.Y. Chen, and K.C. Li Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer J Clin Oncol 30 4 2012 433 440
32. R.M.D. Kudchadkar, K.H.T.M.S. Paraiso, and K.S.M.P. Smalley Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies. [review] Cancer J 18 2 2012 124 131
33. H. Shi, G. Moriceau, and X. Kong Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance Nat Commun 3 2012 724
34. C. Kamby, P.M. Vestlev, and H.T. Mouridsen Site-specific effect of chemotherapy in patients with breast cancer Acta Oncol 31 2 1992 225 229
35. D.N. Jones, G.B. McCowage, and H.D. Sostman Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET J Nucl Med 37 9 1996 1438 1444
36. V. Huyge, C. Garcia, and J. Alexiou Heterogeneity of metabolic response to systemic therapy in metastatic breast cancer patients Clin Oncol 22 10 2010 818 827